The EPS miss and declining revenue reflect near-term headwinds from lumpy collaboration income, but the pipeline advancement in bexobrutideg remains key. Monitor upcoming Phase 2 enrollment data and IND filing for the tablet formulation as catalysts for sentiment reversal.
Price Chart
Executive Summary
Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, and a net loss of $87.2M ($0.79 per share), missing EPS consensus of $-0.73. The miss was driven by lower collaboration revenue as the Sanofi research term wound down, while R&D spending increased to advance bexobrutideg into pivotal trials.
Key Financial Metrics
Key Facts
- Q1 2026 revenue was $6.3M, down from $18.5M in Q1 2025, primarily due to reduced Sanofi collaboration revenue
- EPS of $-0.79 missed consensus of $-0.73 by 7.7%, reflecting higher R&D spend
- R&D expenses rose to $84.1M from $69.7M YoY due to clinical and manufacturing costs for bexobrutideg
- Cash balance was $540.7M as of February 28, 2026, with no near-term liquidity concerns
- Company advancing bexobrutideg in pivotal Phase 2 and planned Phase 3 trials for CLL, with tablet formulation IND targeted in 2026
Financial Impact
Revenue down 66% YoY, EPS miss of 7.7% vs consensus, driven by lower collaboration income and higher R&D spend
Risk Factors
- Dependence on lumpy collaboration revenue creates volatility in financial results
- High R&D spend increases cash burn, though current cash runway appears sufficient
- Clinical trial delays or safety issues in bexobrutideg could negatively impact valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269913 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 29d ago | Insider Cluster | $25.32 $25.10 | ▼ −0.87% | ▲ +0.28% | $22.89 (−9.60%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.22 $27.19 | ▲ +7.81% | ▲ +6.60% | $22.89 (−9.24%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.89 (−8.88%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.89 (−8.88%) |
Aug 3, 2026 8w ago | Insider Cluster | $24.69 $25.96 | ▲ +5.14% | ▲ +5.24% | $22.89 (−7.29%) |
Jul 30, 2026 9w ago | Insider Cluster | $23.21 $25.53 | ▲ +10.00% | ▲ +6.48% | $22.89 (−1.38%) |
Jul 9, 2026 12w ago | Press Release | $23.06 $23.07 | ▲ +0.04% | ▲ +0.60% | $22.89 (−0.74%) |
Jul 2, 2026 13w ago | Insider Cluster | $23.97 $24.69 | ▲ +3.00% | ▲ +2.07% | $22.89 (−4.51%) |
Jun 11, 2026 16w ago | Institutional Cluster | $16.98 $17.12 | ▲ +0.82% | ▲ +0.39% | $22.89 (+34.81%) |
Jun 8, 2026 16w ago | 8-K | $15.64 $17.04 | ▲ +8.95% | ▲ +6.84% | $22.89 (+46.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access